Maplight Therapeutics, INC 10-K annual reports
Annual reports — audited financials, the full risk-factor list, and management’s account of the year.
NASDAQ
MapLight Therapeutics reported a significant net loss in 2025 while progressing its lead CNS drug candidates, ML-007C-MA and ML-004, through Phase 2 clinical trials with key data expected in 2026 and 2027.